Israele - inglese - Ministry of Health

boehringer ingelheim israel ltd. - tiotropium bromide as monohydrate - solution for inhalation - tiotropium bromide as monohydrate 2.5 mcg - tiotropium bromide - maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).copd:tiotropium is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).asthma:spiriva respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.

Israele - inglese - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Israele - inglese - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Israele - inglese - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Israele - inglese - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Australia - inglese - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - bordetella bronchiseptica killed vaccine - misc. vaccines or anti sera - bordetella bronchiseptica killed vaccine vaccine-microbial active 0.0 p - immunotherapy - dog | bitch | castrate | puppy - bordetella bronchiseptica | canine cough syndrome | infectious tracheobronchitis

Nuova Zelanda - inglese - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - copper present as copper disodium edta; selenium present as sodium selenate; disodium cobalt edta; ethylenediamine dihydroiodide; disodium zinc edta; oxfendazole - copper present as copper disodium edta 4.2 g/litre; selenium present as sodium selenate 1 g/litre; disodium cobalt edta 2.7 g/litre; ethylenediamine dihydroiodide 2.5 g/litre; disodium zinc edta 7.3 g/litre; oxfendazole 45.3 g/litre - oral nutrient/electrolyte

Australia - inglese - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - empagliflozin, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - type 2 diabetes mellitus,glycaemic control,jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as:,monotherapy,when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.,add-on combination therapy,in combination with other glucose?lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 pharmacodynamic properties - clinical trials).,prevention of cardiovascular death,jardiance is indicated in patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, jardiance should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.,heart failure,jardiance is indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy (see section 5.1 pharmacodynamic properties - clinical trials).,chronic kidney disease,jardiance is indicated to reduce the risk of kidney disease progression in adults with chronic kidney disease (ckd stages 2 and 3a with urine acr ?30 mg/g, or ckd stages 3b, 4 and 5 irrespective of urine acr).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - empagliflozin, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; hyprolose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - type 2 diabetes mellitus,glycaemic control,jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as:,monotherapy,when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.,add-on combination therapy,in combination with other glucose?lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 pharmacodynamic properties - clinical trials).,prevention of cardiovascular death,jardiance is indicated in patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, jardiance should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.,heart failure,jardiance is indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy (see section 5.1 pharmacodynamic properties - clinical trials).,chronic kidney disease,jardiance is indicated to reduce the risk of kidney disease progression in adults with chronic kidney disease (ckd stages 2 and 3a with urine acr ?30 mg/g, or ckd stages 3b, 4 and 5 irrespective of urine acr).

Stati Uniti - inglese - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aggrenox is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aggrenox is contraindicated in patients with known hypersensitivity to any of the product components. aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. aspirin may cause severe urticaria, angioedema or bronchospasm. do not use aspirin in children or teenagers with viral infections because of the risk of reye syndrome. risk summary available data from published studies and postmarketing experience with aggrenox use during pregnancy have not identified a clear association between aggrenox use and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . aggrenox contains low-dose aspirin which is an nsaid (see clinical considerations) . in animal reproduction studies, there were adverse developmen